Scarica l'app Stockscreener
41.17
6.88%
2.65
Dopo l'orario di chiusura:
41.39
0.22
+0.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$38.52
Aprire:
$40.06
Volume 24 ore:
24.61M
Relative Volume:
1.12
Capitalizzazione di mercato:
$182.60B
Reddito:
$46.77B
Utile/perdita netta:
$15.45B
Rapporto P/E:
11.87
EPS:
3.468
Flusso di cassa netto:
$4.40B
1 W Prestazione:
+1.60%
1M Prestazione:
+11.60%
6M Prestazione:
-22.26%
1 anno Prestazione:
-34.26%
Intervallo 1D:
$39.89
$41.23
Intervallo di 1 settimana:
$38.02
$41.23
Portata 52W:
$35.12
$81.44
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare NVO vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
41.17 | 182.60B | 46.77B | 15.45B | 4.40B | 3.468 |
LLY
Lilly Eli Co
|
883.96 | 789.69B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.50 | 547.64B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
198.71 | 351.47B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
189.75 | 294.27B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
145.47 | 277.58B | 54.72B | 14.02B | 15.32B | 7.1855 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2026-03-18 | Iniziato | Bernstein | Outperform |
| 2026-03-10 | Downgrade | TD Cowen | Buy → Hold |
| 2026-03-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | Downgrade | Goldman | Buy → Neutral |
| 2026-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2026-02-24 | Downgrade | Kepler | Buy → Hold |
| 2026-02-23 | Downgrade | Deutsche Bank | Buy → Hold |
| 2026-02-12 | Aggiornamento | Jefferies | Underperform → Hold |
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2025-12-08 | Downgrade | Argus | Buy → Hold |
| 2025-10-27 | Ripresa | Jefferies | Underperform |
| 2025-10-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-29 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-09-16 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? - The Motley Fool
NVO Stock Price, Quote & Chart | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Novo Nordisk A/S stock (DK0062498333): Is its obesity drug dominance strong enough to sustain long-t - AD HOC NEWS
[6-K] NOVO NORDISK A S Current Report (Foreign Issuer) | NVO SEC FilingForm 6-K - Stock Titan
Novo Nordisk A/S stock (DK0062498333): Is obesity drug dominance strong enough to unlock new upside? - AD HOC NEWS
Novo Nordisk A/S stock (DK0062498333): Is obesity drug dominance strong enough to sustain growth? - AD HOC NEWS
Novo Nordisk A/S stock (DK0062498333): Is its obesity drug dominance strong enough to unlock new ups - AD HOC NEWS
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake - Sahm
NVO Stock Quote Price and Forecast - CNN
NVO Forecast, Price Target & Analyst Ratings | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
UBS (NYSE: UBS) offers autocallable notes tied to Novo Nordisk ADRs due 2027 - Stock Titan
UBS (AMUB) offers autocallable contingent-yield notes linked to Novo Nordisk ADRs - Stock Titan
Novo Nordisk A/S Sponsored ADR Class B Trade Ideas — BMV:NVO/N - TradingView
Novo Nordisk EVOKE Update Raises Questions On Growth Beyond Obesity And Diabetes - Sahm
Novo Nordisk Leans Into Obesity Care With ORION Data And Wegovy Pricing - Sahm
NVO News | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Novo Nordisk Wins EU Nod To Ease Wegovy Injection Delivery - Sahm
Novo Nordisk A/ S stock: Why it's still a powerhouse amid volatility - AD HOC NEWS
Novo Nordisk (NYSE: NVO) details progress in DKK 15B buyback - Stock Titan
Novo Nordisk A/ S stock: Weight-loss boom far from over — what investors need to know - AD HOC NEWS
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novo Nordisk Wegovy Subscription Targets Self Pay Demand And Investor Focus - Sahm
NVO Stock Chart | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Novo Nordisk A/S Stock: Navigating GLP-1 Leadership Amid Evolving Obesity Treatment Landscape - AD HOC NEWS
Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan - Sahm
Novo Nordisk (NYSE: NVO) details progress on DKK 15bn share repurchase - Stock Titan
Novo Nordisk A/S Stock: Pipeline Innovations Amid Share Price Pressures and Market Challenges - AD HOC NEWS
Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program - Sahm
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.17%
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):